论文部分内容阅读
近年关于细胞间粘附分子-1(ICAM-1)与肝细胞癌(HCC)的研究表明,80%～96% HCC 组织中 ICAM-1的表达呈阳性,而血清中 ICAM-1与组织 ICAM-1的表达吻合率为87%;体外实验证实血清 ICAM-1来源于肿瘤细胞表面脱落的 ICAM-1;由于血清 ICAM-1来源及结构的特点,可干扰机体免疫系统对肿瘤的监控,使病情迅速发展;临床上观察到血清 ICAM-1水平与HCC 病情的恶化程度成正比。上述研究结果提示:①测定血清 ICAM-1水平。有可能成为 HCC 早期诊断的血清标记物。②血清 ICAM-1水平可作为 HCC 预后和疗效判断的指标,对提高 HCC 诊治水平具有重要意义。
Recent studies on intercellular adhesion molecule-1 (ICAM-1) and hepatocellular carcinoma (HCC) have shown that ICAM-1 expression is positive in 80% to 96% of HCC tissues, whereas ICAM-1 and ICAM in serum are The rate of expression of -1 was 87%; in vitro experiments confirmed that serum ICAM-1 was derived from ICAM-1 on tumor cell surface shedding; because of the characteristics of the origin and structure of serum ICAM-1, it could interfere with the monitoring of tumor by the body’s immune system. The condition developed rapidly; clinically observed serum ICAM-1 levels are proportional to the degree of deterioration of HCC. The above results suggest that: 1 Determination of serum ICAM-1 levels. It may become a serum marker for early diagnosis of HCC. 2 Serum ICAM-1 level can be used as an indicator of prognosis and curative effect of HCC, which is of great significance in improving the diagnosis and treatment of HCC.